Candriam S.C.A. Intellia Therapeutics, Inc. Transaction History

Candriam S.C.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $926,400 - $1.29 Million	40,000 Added 78.01%	91,275 $2.78 Million
Q3 2023 Nov 13, 2023	SELL	$31.62 - $45.78 $1.26 Million - $1.83 Million	-40,000 Reduced 43.82%	51,275 $1.62 Million
Q4 2022 Feb 13, 2023	SELL	$33.21 - $62.69 $1.66 Million - $3.13 Million	-50,000 Reduced 35.39%	91,275 $3.18 Million
Q2 2022 Aug 03, 2022	BUY	$38.49 - $76.21 $1.55 Million - $3.06 Million	40,148 Added 39.7%	141,275 $7.31 Million
Q2 2021 Jul 20, 2021	SELL	$60.88 - $161.91 $4.98 Million - $13.2 Million	-81,790 Reduced 44.71%	101,127 $16.4 Million
Q4 2020 Jan 22, 2021	BUY	$18.83 - $63.53 $3.44 Million - $11.6 Million	182,917 New	182,917 $9.95 Million
Q4 2019 Jan 21, 2020	SELL	$10.43 - $17.67 $1.25 Million - $2.12 Million	-120,000 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$25.78 - $32.6 $523,334 - $661,780	20,300 Added 20.36%	120,000 $3.43 Million
Q2 2018 Aug 14, 2018	BUY	$20.02 - $30.79 $394,394 - $606,563	19,700 Added 24.63%	99,700 $2.73 Million
Q1 2018 May 09, 2018	BUY	$19.43 - $34.95 $291,450 - $524,250	15,000 Added 23.08%	80,000 $1.69 Million
Q4 2017 Feb 07, 2018	BUY	$17.39 - $31.12 $1.13 Million - $2.02 Million	65,000	65,000 $1.25 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $867M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.